Filter By Category
Archives
Share on -
DACLATASVIR
Generic Name: DACLATASVIR
ABSTRACT -
Daclatasvir is a direct-acting antiviral NS5A inhibitor used in combination regimens for chronic hepatitis C according to local product labeling. It is not used as monotherapy.
DOSAGE -
- Follow the approved local label and genotype-specific regimen.
- A common adult dose in many regimens is once daily with sofosbuvir-based therapy, adjusted for interactions where required.
- Treatment duration depends on genotype, cirrhosis status, prior therapy, and regimen.
SIDE EEFECTS -
- Headache, fatigue, nausea, diarrhea, insomnia, or anemia may occur depending on regimen.
- Liver function changes can occur, especially in advanced liver disease.
- Bradycardia risk is notable when sofosbuvir regimens are combined with amiodarone.
ALLERGIC REACTIONS -
- Immediate rash, hives, itching, flushing, or generalized skin reaction
- Facial, lip, tongue, or throat swelling
- Wheezing, chest tightness, shortness of breath, or severe dizziness
- Severe hypotension, collapse, or anaphylaxis requires emergency care
- Any suspected allergy should be documented and reported to future healthcare providers
DRUG INTERACTIONS-
- Strong CYP3A inducers may reduce exposure and are generally avoided.
- CYP3A/P-gp inhibitors or inducers may require dose adjustment or avoidance.
- Check interactions with antiretrovirals, anticonvulsants, rifamycins, and herbal products.
PREAUTONS–
- Screen for hepatitis B before starting HCV direct-acting antiviral therapy.
- Assess liver disease severity, pregnancy status, HIV/HBV coinfection, and drug interactions.
- Monitor adherence and virologic response.
WARNINGS –
- HBV reactivation can occur with HCV direct-acting antivirals in coinfected patients.
- Severe bradycardia may occur with sofosbuvir plus amiodarone-containing regimens.
- Keep out of reach of children.
Share on -
. Developed by